Can Over-Treating Wilson Disease with Chelation Damage My Nerves?

If your copper levels have dropped very low on chelation therapy and you are developing new neurological symptoms — numbness, weakness, unsteady gait, or worsening coordination — take this seriously and contact your specialist promptly. Over-chelation, meaning the removal of more copper than your body can tolerate, is a known and documented complication of Wilson disease treatment. It is treatable, but only if caught.

Two separate problems that can both cause neurological symptoms

Before going further, it is important to distinguish between two different processes that can cause neurological worsening in Wilson disease:

Early neurological worsening (paradoxical worsening) occurs in some patients — particularly those with neurological Wilson disease — at the beginning of chelation therapy, often within weeks of starting penicillamine or trientine. The prevailing theory is that chelation mobilises copper from the liver into the blood faster than the brain can handle, temporarily raising brain copper exposure.¹ This is different from what you are describing if you have been on treatment for a while.

Copper deficiency from over-chelation is what happens after prolonged or excessive chelation has stripped the body’s copper below the normal physiological range. Copper is not just a toxin in Wilson disease — it is an essential trace element that every cell needs. It is critical for nerve function, blood cell production, bone metabolism, and immune response.² When chelation removes too much, the result is a secondary copper deficiency that can cause its own neurological damage, largely independent of Wilson disease itself.

You can read more about the neurological worsening that can occur at the start of treatment at the medications overview.

What copper deficiency does to the nervous system

The neurological syndrome associated with copper deficiency — whether from over-chelation, malabsorption, or excess zinc — has a characteristic pattern. It resembles subacute combined degeneration of the spinal cord: patients develop peripheral neuropathy (numbness or tingling in the hands and feet, often with a “stocking-glove” distribution), myelopathy (weakness, spasticity, difficulty walking), or both.³

A 2020 case report described a patient with Wilson disease who developed exactly this picture on zinc therapy — copper had been reduced so far that iatrogenic deficiency caused new neurological symptoms, which were mistaken at first for Wilson disease progression.³ The lesson from that and similar cases is that the direction of the error matters: too little copper removal allows Wilson disease to progress; too much creates a new, iatrogenic problem.

A 2015 MRI-based study of patients who worsened neurologically during penicillamine treatment found that oxidative stress markers and specific brain MRI changes correlated with the neurological deterioration, providing imaging evidence that these were real, measurable injuries — not subjective complaints.⁴

When does over-chelation actually happen?

Over-chelation severe enough to cause symptoms is uncommon in patients under regular specialist monitoring, but it can occur in several circumstances:

• When the chelation dose is never adjusted downward after the initial decoppering phase is complete. Chelators typically need to be reduced once copper levels normalise; continuing the full induction dose indefinitely increases cumulative risk.
• When a patient’s diet or health changes in ways that reduce copper intake (long-term restricted diets, malnutrition), making a previously appropriate dose excessive.
• When zinc is prescribed at too high a dose, or for too long without monitoring, for a patient whose copper was already at the lower end of normal.
• When laboratory monitoring lapses and no one notices that copper has been drifting below the therapeutic range.

The 2022 AASLD Practice Guidance specifies target ranges for 24-hour urinary copper excretion and non-ceruloplasmin-bound copper in treated patients, precisely because staying within a defined window — rather than simply “as low as possible” — is the goal.⁵ Below a certain threshold, the risk of deficiency rises without any additional benefit.

What are the signs to watch for?

Copper deficiency from over-chelation tends to develop slowly. Early signs can be subtle:

System	Early signs	Later signs
Nervous system	Tingling in hands/feet, mild unsteadiness	Weakness, difficulty walking, myelopathy
Blood	Mild anaemia, low neutrophils on blood count	Severe pancytopenia
Metabolism	Fatigue, poor wound healing	Bone fragility

The anaemia and neutropenia (low white cell count) are important clinical clues because they are measurable on a routine full blood count. If your blood tests show low neutrophils or unexplained anaemia at the same time as low serum copper, copper deficiency should be near the top of the list.

What should you do right now?

If you have new neurological symptoms and you know your copper has been reading very low, do not wait for your next scheduled appointment. Call your specialist and describe what you are experiencing. The workup will typically include:

• Serum copper and ceruloplasmin
• Non-ceruloplasmin-bound copper
• Full blood count (to check for anaemia and neutrophil count)
• Possibly an MRI of the cervical and thoracic spine if spinal cord involvement is suspected

Treatment of over-chelation is usually dose reduction or temporary interruption of the chelator. In some cases of overt deficiency, copper supplementation may be introduced under careful supervision — with doses managed very precisely, since copper supplementation in a Wilson disease patient requires expert oversight.⁶

The monitoring safety net

This situation is one of the strongest arguments for never missing monitoring appointments. The 24-hour urinary copper test and the non-ceruloplasmin copper assay together give your team the information they need to keep you in the therapeutic window — enough copper removed to prevent Wilson disease progression, not so much that copper deficiency develops.

A 2025 study emphasised the importance of standardised 24-hour urine copper monitoring, noting that interpretation depends on whether the sample is taken while the patient is on therapy or during a planned interval off it, and that protocol variations can make comparisons unreliable.⁷ This underscores the value of a consistent, well-documented monitoring approach rather than ad hoc testing.

If your copper levels have been at or near the lower limit of the target range for some time, or if your specialist has not reviewed your chelator dose recently, this is an important conversation to initiate — ideally before new symptoms emerge.

This article is for patient education only. New neurological symptoms in a patient on Wilson disease treatment always warrant prompt medical evaluation. Please contact your specialist or, if symptoms are severe or rapidly progressing, seek urgent care.

References